Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 3/20 | 0.51 |
| ▸ | THRB | P10828 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | RXRA | P19793 | 2/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGAV | P06756 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30448708 | 1.00 | THRA (0.51) | THRATHRBPPARGRXRAITGB3 | |
| SCHEMBL4036461 | 0.88 | GPR35 (0.52) | MEN1KMT2ACYP1A2CYP2C9HPGD | |
| SCHEMBL5708442 | 0.86 | MEN1 (0.43) | THRATHRBPPARGRXRAITGB3 | |
| SCHEMBL7673210 | 0.83 | MEN1 (0.39) | THRATHRBPPARGRXRAITGB3 | |
| SCHEMBL11156541 | 0.83 | TTR (0.53) | LMNAMEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL6647574 | 0.82 | HSP90AB1 (0.49) | THRATHRBPPARGRXRAITGB3 | |
| SCHEMBL8773706 | 0.80 | THRB (0.71) | THRATHRBPPARGRXRAITGB3 | |
| SCHEMBL5879457 | 0.78 | ESR1 (0.39) | THRATHRBPPARGRXRAITGB3 | |
| SCHEMBL11083679 | 0.77 | MEN1 (0.44) | LMNAMEN1KMT2AHTTCYP1A2 | |
| SCHEMBL1258900 | 0.77 | MEN1 (0.44) | LMNAMEN1KMT2AHTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1524988-B1 | USE OF A PROTEASOME INHIBITOR IN THE TREATMENT OF FIBROTIC DISEASES | CHARITE UNIVERSITAETSMEDIZIN (DE) | 2008-04-16 | — | — | EP | claimed |
| US-20060199772-A1 | Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy | CHARITE'-UNIVERSITAETSMEDIZIN BERLIN (DE) | 2006-09-07 | — | — | US | claimed |
| US-20050222043-A1 | Use of proteasome inhibitor in the treatment of fibrotic diseases | CHARITE-UNIVERSITAETSMEDIZIN BERLIN (DE) | 2005-10-06 | — | — | US | claimed |
| EP-1524977-A2 | USE OF A PROTEASOME INHIBITOR IN THE TREATMENT OF ENDOTHELIAL DYSFUNCTION AND/OR IN A LOW-DOSE PROTEASOME INHIBITOR THERAPY | Charité - Universitätsmedizin Berlin (DE) | 2005-04-27 | — | — | EP | claimed |
| WO-2004012732-A2 | USE OF A PROTEASOME INHIBITOR IN THE TREATMENT OF ENDOTHELIAL DYSFUNCTION AND/OR IN A LOW-DOSE PROTEASOME INHIBITOR THERAPY | Charité-Universitätsmedizin Berlin (DE) | 2004-02-12 | — | — | WO | claimed |
| US-12630643-B2 | CD40 binding protein, bispecific conjugate thereof and method of treating cancer | STRIKE PHARMA AB (SE) | 2026-05-19 | — | — | US | disclosed |
| US-20260083778-A1 | GENERATION OF CD4 T CELLS | BOSTON MEDICAL CENTER CORPORATION (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4659813-A2 | ENGINEERED IMMUNOGLOBULINS WITH ALTERED FCRN BINDING | Universitetet I Oslo (NO) | 2025-12-10 | — | — | EP | disclosed |
| EP-3835318-B1 | FC-REGION VARIANTS WITH MODIFIED FCRN- AND MAINTAINED PROTEIN A-BINDING PROPERTIES | HOFFMANN LA ROCHE (CH) | 2025-10-29 | — | — | EP | disclosed |
| EP-3430039-B1 | ENGINEERED IMMUNOGLOBULINS WITH ALTERED FCRN BINDING | UNIV OSLO (NO) | 2025-10-22 | — | — | EP | disclosed |
| US-20250263487-A1 | METHODS TO MANIPULATE ALPHA-FETOPROTEIN (AFP) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250248980-A1 | IMMUNE MODULATORY AGENTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-08-07 | — | — | US | disclosed |
| WO-1992001047-A1 | METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS | CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED (GB) | 1992-01-23 | — | — | WO | disclosed |
| WO-1991001368-A1 | HAPTEN/ANTI-HAPTEN AFFINITY LINKING IN CELL SEPARATION | DYNAL A.S. (NO) | 1991-02-07 | — | — | WO | disclosed |
| WO-1991001335-A1 | IgG3 ANTIBODIES WITH SHORTENED HINGE REGION AND A COMPLEMENT ACTIVATION TEST | DYNAL A.S. (NO) | 1991-02-07 | — | — | WO | disclosed |
| EP-0396505-A2 | Monoclonal antibodies specific for an immunoglobulin isotype | CIBA-GEIGY AG (CH) | 1990-11-07 | — | — | EP | disclosed |
| EP-0334300-A1 | The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites | NEORX CORPORATION (US) | 1989-09-27 | — | — | EP | disclosed |
| EP-0267779-A2 | Human pleiotropic immune factor and muteins thereof | Schering Biotech Corporation (US) | 1988-05-18 | — | — | EP | disclosed |
| US-4536479-A | DETECTION ON NONIMMUNOGLOBOLIN ANALYTE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-08-20 | — | — | US | disclosed |
| EP-0119629-A2 | Use of anti-idiotype antibodies in immunoassay | NEW ENGLAND NUCLEAR CORPORATION (US) | 1984-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248980-A1 | IMMUNE MODULATORY AGENTS | IL2, IL17A, IL2RA | THRA 1685/4885THRB 1234/4885PPARG 1491/4885 |
| US-12630643-B2 | CD40 binding protein, bispecific conjugate thereof and method of treating cancer | CD40, CD40LG, IGSF11 | THRA 200/4885THRB 265/4885PPARG 3103/4885 |
| US-20260083778-A1 | GENERATION OF CD4 T CELLS | CD4, CD2, ICOS | THRA 1808/4885THRB 1173/4885PPARG 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.